MedWatch

Novo Holdings considers sale of Xellia Pharmaceuticals

Novo Nordisk Foundation's investment company is examining opportunities for the sale of Xellia Pharmaceuticals.

Photo: Xellia Pharmaceuticals PR

Sources have told Bloomberg News that Novo Holdings is currently investigating its options for a possible sale of Xellia Pharmaceuticals, which is headquartered in Amager, Copenhagen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs